Page 1 of 35

Rationale for Matching ICD-9 Codes to 

ICD-10 Codes for Predetermined Organ and 

IREP Model Selections

ORAUT-RPRT-0098 Rev. 00

Effective Date: 07/22/2019

Supersedes: None

Subject Expert(s): Victoria G. Brown, David Allen, Scott R. Siebert

Document Owner 

Approval: Signature on File

Scott R. Siebert, Document Owner

Approval Date: 07/06/2019

Concurrence: Signature on File

Scott R. Siebert, Objective 3 Manager

Concurrence Date: 07/06/2019

Concurrence: Vickie S. Short Signature on File for

Kate Kimpan, Project Director

Concurrence Date: 07/08/2019

Approval: Signature on File

Timothy D. Taulbee, Associate Director for Science

Approval Date: 07/22/2019

FOR DOCUMENTS MARKED AS A TOTAL REWRITE, REVISION, OR PAGE CHANGE, REPLACE THE PRIOR 

REVISION AND DISCARD / DESTROY ALL COPIES OF THE PRIOR REVISION.

New Total Rewrite Revision Page Change
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 2 of 35

 

PUBLICATION RECORD

EFFECTIVE

DATE

REVISION

NUMBER DESCRIPTION

07/22/2019 00-A New draft report initiated to document the rationale for matching 

ICD-9 codes to ICD-10 codes for predetermined organ and model 

selections in the Interactive RadioEpidemiological Program. 

Incorporates formal internal and NIOSH review comments. Training 

required: As determined by the Objective Manager. Initiated by 

Scott R. Siebert.
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 3 of 35

 

TABLE OF CONTENTS

SECTION TITLE PAGE

Acronyms and Abbreviations.................................................................................................................. 4

1.0 Introduction ................................................................................................................................. 5

2.0 Determining ICD-10 Codes......................................................................................................... 5

2.1 Resources ....................................................................................................................... 5

2.2 ICD-10 Codes Not Covered by EEOICPA ...................................................................... 6

2.3 Corresponding ICD-9 and ICD-10 codes ........................................................................ 6

3.0 Primary ICD-10 Codes Requiring Additional Review.................................................................. 7

3.1 Primary NonLymphoma ICD-10 Codes........................................................................... 8

3.2 Primary Lymphoma ICD-10 Codes ...............................................................................16

4.0 Secondary Cancer ICD-10 Codes ............................................................................................23

4.1 Corresponding ICD-9 and ICD-10 Secondary Cancer Codes.......................................24

4.2 Corresponding ICD-9 and ICD-10 Likely Primary Cancer Codes ................................. 26

4.3 ICD-10 Version of NIOSH (2002) Table 7 .....................................................................27

5.0 Conclusion ................................................................................................................................32

References ...........................................................................................................................................34

LIST OF TABLES

TABLE TITLE PAGE

2-1 ICD-10 codes in the C00 to D49 range not covered by EEOICPA ............................................. 6

4-1 NIOSH (2002) Table 7 ..............................................................................................................24

4-2 Corresponding ICD-9 and ICD-10 likely primary cancer codes ................................................27

4-3 ICD-10 version of IREP Technical Documentation Table 7 ......................................................27

4-4 Organ and IREP model selection for likely primary ICD-10 codes ...........................................30

4-5 ICD-10 codes with identical organ and IREP model selection..................................................32

4-6 ICD-10 version of IREP Technical Documentation Table 7 for use in EEOICPA .....................33
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 4 of 35

ACRONYMS AND ABBREVIATIONS

ALK anaplastic lymphoma kinase

CFR Code of Federal Regulations

DOL U.S. Department of Labor

EEOICPA Energy Employees Occupational Illness Compensation Program Act of 2000

ICD-10-CM International Classification of Diseases, Tenth Revision, Clinical Modification

ICD-9 International Classification of Diseases, Ninth Revision

IREP Interactive RadioEpidemiological Program

NCHS National Center for Health Statistics

NIOSH National Institute for Occupational Safety and Health

NK/T natural killer T-cell

NOS not otherwise specified

ORAU Oak Ridge Associated Universities

SRDB Ref ID Site Research Database Reference Identification (number)

WHO World Health Organization
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 5 of 35

1.0 INTRODUCTION

The National Center for Health Statistics (NCHS) is responsible for developing the International 

Statistical Classification of Diseases and Related Health Problems in the United States. NCHS has 

adapted the World Health Organization (WHO) classification to develop the International Classification 

of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) for use by the U.S. government and 

its agencies. ICD-10-CM and its codes officially replaced the International Classification of Diseases, 

Ninth Revision (ICD-9, Volumes 1 and 2) on October 1, 2015. NCHS issues updates to ICD-10-CM

and its codes each year (NCHS 2018a).

The U.S. Department of Labor (DOL) began sending both ICD-9 and ICD-10 codes for use in Energy 

Employees Occupational Illness Compensation Program Act of 2000 (EEOICPA) claims in 

approximately 2014. However, DOL has informed the National Institute for Occupational Safety and 

Health (NIOSH) that beginning in 2019 they will send only ICD-10 codes for EEOICPA claims. To 

ensure consistency in organ and Interactive RadioEpidemiological Program (IREP) model selection, it 

is necessary to conduct a conversion from ICD-9 codes to ICD-10 codes for use in Oak Ridge 

Associated Universities (ORAU) Team technical information bulletins ORAUT-OTIB-0005, Internal 

Dosimetry Organ, External Dosimetry Organ, and IREP Model Selection by ICD-9 Code (ORAUT 

2012) and ORAUT-OTIB-0006, Dose Reconstruction from Occupational Medical X-Ray Procedures

(ORAUT 2018). 

This document provides the rationale for matching ICD-9 codes to ICD-10 codes for predetermined 

external organ, internal organ, and IREP model selections in preparation for converting other 

documents to ICD-10 codes for use when DOL begins including only ICD-10 codes in NIOSH Referral 

Summary Documents. However, since the predetermined external organ is not always appropriate for 

the X-ray organ selection, additional consideration will need to be made for each ICD-10 code to 

ensure the appropriate X-ray organ is selected in ORAUT-OTIB-0006. 

2.0 DETERMINING ICD-10 CODES

2.1 RESOURCES

To determine the appropriate ICD-10 codes for comparison with the ICD-9 codes presently in 

ORAUT-OTIB-0005, resources from NCHS were used based on the 2018 version of ICD-10-CM. The 

2018 version was selected based on the availability of General Equivalence Maps for conversions 

from ICD-9 to ICD-10 and conversions from ICD-10 to ICD-9, as well as ICD-10 code descriptions

(NCHS 2018b to 2018e).

The ICD-9 coding system currently used in ORAUT-OTIB-0005 has a general range of codes from 

140 to 239 to describe cancers. There are some exceptions inside this range, which do not describe 

cancers and some exceptions outside this range, which do describe cancers. Similarly, the ICD-10 

coding system has a general range of codes from C00 to D49 to describe cancers (with similar 

exceptions inside and outside that range). Because the exceptions are codes that need special 

consideration to ensure they are not missed, the NCHS conversion from ICD-9 to ICD-10 codes was 

examined and reduced to those entries that have ICD-9 codes in ORAUT-OTIB-0005. This showed 

that the majority of the corresponding ICD-10 codes were in the C00 to D49 range as expected, with 

the exception of codes D68, D74, D75, D89, E31, J91, Q85, and R18. Using the listing of ICD-10 

code descriptions from NCHS (2018f), a listing of ICD-9 codes in ORAUT-OTIB-0005 and 

corresponding ICD-10 codes with descriptions were assembled in ORAUT (2019) for use in this 

process.
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 6 of 35

 

2.2 ICD-10 CODES NOT COVERED BY EEOICPA 

The list of all ICD-10 codes with descriptions in ORAUT (2019) was reviewed to determine which 

codes should be considered under EEOICPA (i.e., codes describing cancer). After ensuring that all 

ICD-9 codes presently in ORAUT-OTIB-0005 were retained with a corresponding ICD-10 code, the 

ICD-10 codes outside the expected general range were reviewed. As mentioned earlier, with some 

small exceptions (i.e., ICD-10 codes D68, D74, D75, D89, E31, J91, Q85, and R18), the overall ICD10 codes for cancers fell within the C00 to D49 range. To determine if any of these exceptions 

described a cancer diagnosis, the ICD-10 subcodes for each were examined. With the exclusion of 

those exceptions that had a direct conversion to an ICD-9 code in ORAUT-OTIB-0005, the rest were 

determined not to reflect codes for cancer and were removed.

To ensure no ICD-10 cancer codes outside the general range of C00 to D49 were missed, the 

remaining ICD-10 codes (i.e., A-B and D50-Z) were reviewed. ICD-10 code D77 was determined to 

correspond to ICD-9 code 289.89 in ORAUT-OTIB-0005 and was kept on the list for consideration. 

The remaining ICD-10 codes were determined not to reflect codes for cancer and were removed from 

the list.

The range of codes from C00 to D49 also includes benign cancers, which are not covered under 

EEOICPA, so these codes were examined to determine which described benign cancers. The 

following ICD-10 codes were determined to describe benign cancers and were removed from the list: 

D10.0 to D17.9, D19.0 to D21.9, D23.0 to D24.9, D26.0 to D36.9, and D3A.0 to D3A.8.

In addition, codes within the C00 to D49 range that did not have a corresponding ICD-9 code in 

ORAUT-OTIB-0005 were examined to determine if they described cancer. Table 2-1 lists ICD-10 

codes that were removed because they do not describe cancer.

Table 2-1. ICD-10 codes in the C00 to D49 range not covered by EEOICPA.

ICD-10 code(s) Disease description Reason disease is not covered

C80.2 Malignant neoplasm associated with 

transplanted organ

Condition based on transplanted organ

C96.5 and C96.6 Langerhans-cell histiocytosis Does not appear to be cancer and no 

corresponding cases have been received by DOL

D18.0–D18.09 Hemangioma Non-cancerous blood vessel growth

D18.1 Lymphangioma Non-malignant

D22.0–D22.9 Melanocytic nevi Benign growths

D25.0–D25.9 Leiomyoma Benign growths

D47.2 Monoclonal gammopathy Benign condition of abnormal plasma cells

D47.Z1 Post-transplant lymphoproliferative 

disorder

Condition based on transplanted organ

2.3 CORRESPONDING ICD-9 AND ICD-10 CODES

While developing the list of ICD-10 codes covered under EEOICPA, it was determined that many of 

the ICD-10 codes directly corresponded to ICD-9 codes presently listed in ORAUT-OTIB-0005. 

However, some ICD-10 codes did not have a clear one-to-one correspondence to an ICD-9 code 

listed in ORAUT-OTIB-0005. These codes were separated into two groups for further review:

1. Those where an ICD-10 code corresponded to more than one ICD-9 code (duplicate), and

2. Those where the ICD-10 code corresponded to only one ICD-9 code.

A total of 69 ICD-10 codes corresponded to more than one ICD-9 code, resulting in 191 entries 

needing additional review. These codes were reviewed to determine if there was consistency 
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 7 of 35

 

between the duplicate codes (i.e., appropriate ICD-9 description, internal organ, external organ, and 

IREP model) or not.

Out of the remaining 1,321 ICD-10 codes that corresponded to only one ICD-9 code, 948 of these 

codes did not have a clear one-to-one correspondence to an ICD-9 code listed in ORAUT-OTIB-0005. 

In addition, there were two ICD-10 codes that had a clear one-to-one correspondence with an ICD-9 

code, but in ORAUT-OTIB-0005 those ICD-9 codes were broken down into multiple options for 

different cancer organs described by the same code. Therefore, all of these codes were reviewed to 

determine if the ICD-9 code information appeared appropriate, even if only an approximation, or if 

further review would be necessary to make an accurate determination of the internal organ, external 

organ, and IREP model that should be used. The remaining 373 ICD-10 codes that were not marked 

for review were assumed to be acceptable as a one-to-one correspondence to their ICD-9 codes.

As a result of this review process it was determined that 197 ICD-10 codes (i.e., 31 ICD-10 codes with 

duplicates and 166 ICD-10 codes without duplicates) required additional review to determine the 

appropriate internal organ, external organ, and IREP model for use in EEOICPA. 

Of the 197 total ICD-10 codes requiring additional review, 122 of them were for a type of lymphoma. 

Because lymphomas were so predominant in the list of ICD-10 codes requiring additional review, the 

entire list of lymphomas was reviewed, including those already deemed acceptable. The lymphoma 

ICD-10 codes encompass a range of 363 codes between C81 and C89. This resulted in a total of 

438 ICD-10 codes requiring additional review to determine the appropriate corresponding ICD-9 code

for organ and IREP model selection. 

3.0 PRIMARY ICD-10 CODES REQUIRING ADDITIONAL REVIEW 

The goal of this evaluation was to determine the best matching ICD-9 code for each ICD-10 code so 

that the predetermined organs and cancer models from ORAUT-OTIB-0005 can be transferred to the 

new ICD-10 codes. This evaluation assumes ORAUT-OTIB-0005 is correct and complete. It does 

not reevaluate the organs and models for those codes. In some cases, the corresponding ICD-9 code 

was chosen based only on the appropriateness of the internal organ, external organ, and IREP model, 

not the appropriate medical diagnosis.

Due to the number of questionable lymphoma ICD-10 codes between C81 and C89, a review of all of 

the lymphoma codes was conducted and is discussed separately in Section 3.2. 

The following discussion provides the rationale for the selection of the most appropriate ICD-9 code 

for each ICD-10 code that required additional review. The rationale for each ICD-10 code is 

presented in the following format: 

1. ICD-10 code(s) – Description

a. Corresponding ICD-9 code from initial review – Description

i. If ICD-10 code corresponds to multiple ICD-9 codes; ICD-9 Code – Description

b. Rationale

c. ICD-9 code to be used for organ and IREP model selection for ICD-10 code – Description; 

or other decision
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 8 of 35

3.1 PRIMARY NONLYMPHOMA ICD-10 CODES

1. C72.20 to C72.59 – Malignant neoplasm of olfactory, optic, acoustic, and unspecified cranial 

nerves

a. 192.0 – Malignant neoplasm of cranial nerves

b. ICD-10 code C72 has subcodes for various nerves in the head, whereas ICD-9 has two 

codes for the nervous system, 191 – brain and 192 – all other parts of nervous system. In 

ORAUT-OTIB-0005, the internal organ, external organ, and IREP model are identical for all 

191 and 192 ICD-9 subcodes.

c. 192.0 – Malignant neoplasm of cranial nerves

2. C90.20 to C90.22 – Extramedullary plasmacytoma

a. 203.80 to 203.82 – Other immunoproliferative neoplasms

b. ICD-10 code C90 refers to multiple myelomas and malignant plasma cell neoplasms, and 

is broken down into the following subcodes: C90.0 – multiple myeloma, C90.1 – plasma 

cell leukemia, C90.2 – extramedullary plasmacytoma, and C90.3 – solitary plasmacytoma. 

This implies that C90.2 and C90.3 are either a form of multiple myeloma or plasma cell 

leukemia. The corresponding ICD-9 codes for the C90 ICD-10 codes are 203.0 – multiple 

myeloma, 203.1 – plasma cell leukemia, and 203.8 – other immunoproliferative 

neoplasms. All three ICD-9 codes use the same internal organ, external organ, and IREP 

model in ORAUT-OTIB-0005.

c. 203.80 to 203.82 – Other immunoproliferative neoplasms

3. C90.30 to C90.32 – Solitary plasmacytoma

a. 203.80 to 203.82 – Other immunoproliferative neoplasms

b. See discussion for C90.20 to C90.22.

c. 203.80 to 203.82 – Other immunoproliferative neoplasms

4. C91.A0 to C91.A2 – Mature B-cell leukemia Burkitt-type

a. 204.80 to 204.82 – Other lymphoid leukemia

b. ICD-9 code 204.8 is essentially a generic classification for all other lymphoid leukemias not 

elsewhere classified. ICD-10 coding specified Burkitt-type leukemia instead of grouping it 

with “all other” types. In addition, Burkitt-type leukemia is a different cancer diagnosis than 

Burkitt lymphoma (ICD-10 code C83.7, ICD-9 code 200.2).

c. 204.80 to 204.82 – Other lymphoid leukemia

5. C92.20 to C92.22 – Atypical chronic myeloid leukemia

a. 205.20 to 205.22 – Subacute myeloid leukemia

b. An associate professor of medicine, board certified in hematology, stated that he “was not 

sure what subacute leukemia is” (NIOSH ca. 2005). It appears that WHO simply changed 

the name of this diagnosis to something more acceptable, indicating it is not quite acute 

(subacute) and not quite chronic (atypical chronic). The cancer model for this “subacute” 
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 9 of 35

 

cancer was specified in the technical documentation for IREP, and this name change from 

“subacute” to “atypical chronic” does not appear to be a good reason to change the organs 

or IREP model for this cancer.

c. 205.20 to 205.22 – Subacute myeloid leukemia

6. C93.30 to C93.32 – Juvenile myelomonocytic leukemia

a. 206.80 to 206.82 – Other monocytic leukemia

b. Although this code appears to be intended for children, there is a history of some energy 

employees under the age of 18 in EEOICPA. Therefore, this code should remain in the list 

of cancers in ORAUT-OTIB-0005. 

c. Retain C93.30 to C93.32 corresponding to 206.8 – Other monocytic leukemia

7. C94.30 to C94.32 – Mast cell leukemia

a. 207.80 to 207.82 – Other specified leukemia

b. Mast cell leukemia is a different cancer diagnosis than mast cell lymphoma (ICD-10 code

to C96.2). In addition, all ICD-9 codes for other leukemia diagnosis in ORAUT-OTIB-0005

use the same internal organ, external organ, and IREP model.

c. 207.80 to 207.82 – Other specified leukemia

8. C94.40 to C94.42 – Acute panmyelosis with myelofibrosis

a. 238.79 – Neoplasm of uncertain behavior of other lymphatic/hematopoietic tissue

b. ICD-9 did not have a code specific to acute panmyelosis with myelofibrosis; however, the 

238.7 group of ICD-9 codes includes myelodysplastic syndrome and myelofibrosis with 

myeloid metaplasia. From the name, C94.4 appears to fall into the 238.7 group of ICD-9 

codes and all 238.7 codes use the same external organ, internal organ, and IREP model.

c. 238.79 – Neoplasm of uncertain behavior of other lymphatic/hematopoietic tissue

9. C94.6 – Myelodysplastic disease, not classified

a. 238.79 – Neoplasm of uncertain behavior of other lymphatic/hematopoietic tissue

b. According to the National Cancer Institute (2019) this unclassified version shows features 

of both myeloproliferative disease and myelodysplastic disease, therefore it is not 

classified as either. All forms of classified myelodysplastic disease are under ICD-10 code 

D46. The corresponding ICD-9 codes for D46 are within the 238.7 group and use the 

same internal organ, external organ, and IREP model as 238.79.

c. 238.79 – Neoplasm of uncertain behavior of other lymphatic/hematopoietic tissue

10. C95.90 to C95.92 – Leukemia, unspecified

a. Corresponded to multiple ICD-9 codes

i. 208.2 – Subacute leukemia
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 10 of 35

ii. 208.8 – Other leukemia unspecified

iii. 208.9 – Other leukemia not otherwise specified

b. The corresponding ICD-9 codes use the same internal organ and external organ, but 

different IREP models. ICD-9 codes 208.2 and 208.8 indicate known types of leukemia 

that do not have their own specific code, whereas 208.9 is for a leukemia of unknown type. 

In addition, 208.9 uses all possible IREP models for leukemia and is the most claimant

favorable of the three ICD-9 codes.

c. 208.9 – Other leukemia not otherwise specified

11. C96.20 to C96.29 – Malignant mast cell neoplasms

a. 202.60 to 202.68 – Malignant mast cell neoplasms of specific locations

b. ICD-9 specified various locations for the site of this cancer while ICD-10 does not. The 

locations described in ICD-9 dictated the appropriate organ to use in ORAUT-OTIB-0005, 

but all 202.6 ICD-9 subcodes use the same IREP model.

c. Require a medical review for internal and external organs using 202.6 lymphoma location 

scheme and IREP model. If medical review is inconclusive, use organ selection for 

202.60, because this is the most claimant-favorable organ and IREP model selection.

12. C96.4 – Sarcoma of dendritic cells (accessory cells)

a. 202.90 – Other malignant neoplasm of lymphoid and histiocytic tissue of unspecified organ

b. In the hierarchy of ICD-10 codes, C81 to C88 specify lymphomas, while C90 to C95 

specify leukemias and multiple myeloma (there is no C89 code). C96 specifies “Other and 

unspecified malignant neoplasms of lymphoid, hematopoietic and related tissues,” which 

essentially includes anything not captured in the other codes between C81 and C95. In 

the hierarchy of ICD-9, 202 specifies “Other malignant neoplasms of lymphatic or 

hematopoietic tissue,” which appears to be a good match of C96. 202.1 through 202.7 

specify specific cell types while 202.8 is for “lymphomas not elsewhere classified” and 

202.9 is for “lymphoid and histiocytic tissue.” In ORAUT-OTIB-0005, 202.8 and 202.9 

designate the same internal and external organs and cancer model.

c. 202.9 – Malignant neoplasm of lymphoid and histiocytic tissue

13. C96.Z – Other specified malignant neoplasm of lymphoid, hematopoietic and related tissues

a. 202.90 – Other malignant neoplasm of lymphoid and histiocytic tissue of unspecified organ

b. See discussion for C96.4.

c. 202.9 – Malignant neoplasm of lymphoid and histiocytic tissue

14. D01.1 – Carcinoma in situ of rectosigmoid junction

a. 230.4 – Carcinoma in situ of rectum

b. ICD-9 code 230.4 is for the rectum but not necessarily the rectosigmoid junction. 

However, ICD-9 codes 230.5 and 230.6 are for “anal canal” and “anus NOS [not otherwise 

specified],” respectively. All three codes have the same internal organ, external organ, and 

IREP model. Additionally, ICD-9 code 154.0 is for malignant neoplasms of the 
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 11 of 35

 

rectosigmoid junction and also uses the same internal organ, external organ, and IREP 

model.

c. 230.4 – Carcinoma in situ of rectum

15. D09.3 – Carcinoma in situ of thyroid and other endocrine glands

a. 234.8 – Carcinoma in situ not elsewhere classified

b. There is no ICD-9 code for carcinoma in situ of the thyroid or any other endocrine gland. 

For the purposes of organ and IREP model selection in EEOICPA, there should be no 

difference between a malignant neoplasm and a carcinoma in situ. Therefore, the organ 

and IREP model selection for D09.3 should correspond to ICD-9 codes 193 and 194, 

malignant neoplasm of thyroid and other endocrine glands.

c. 193 and 194.0 to 194.9 – Malignant neoplasm of thyroid and other endocrine glands, 

requiring a medical review to determine which location is most appropriate.

16. D37.01 – Neoplasm of uncertain behavior lip

a. 235.1 – Neoplasm of uncertain behavior oral pharynx

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 140.9 – Malignant neoplasm lip NOS

17. D37.1 – Neoplasm of uncertain behavior stomach

a. 235.2 – Neoplasm of uncertain behavior stomach, intestine, and rectum

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 151.9 – Malignant neoplasm stomach NOS

18. D37.2 – Neoplasm of uncertain behavior small intestine

a. 235.2 – Neoplasm of uncertain behavior stomach, intestine, and rectum

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 152.9 – Malignant neoplasm small bowel NOS

19. D37.3 – Neoplasm of uncertain behavior appendix

a. 235.2 – Neoplasm of uncertain behavior stomach, intestine, and rectum
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 12 of 35

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 153.5 – Malignant neoplasm appendix

20. D37.4 – Neoplasm of uncertain behavior colon

a. 235.2 – Neoplasm of uncertain behavior stomach, intestine, rectum

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 153.9 – Malignant neoplasm colon NOS

21. D37.5 – Neoplasm of uncertain behavior rectum

a. 235.2 – Neoplasm of uncertain behavior stomach, intestine, rectum

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 154.1 – Malignant neoplasm rectum

22. D38.3 – Neoplasm of uncertain behavior mediastinum

a. 235.8 – Neoplasm of uncertain behavior pleura

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 164.9 – Malignant neoplasm mediastinum NOS

23. D38.4 – Neoplasm of uncertain behavior thymus

a. 235.8 – Neoplasm of uncertain behavior pleura

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 164.0 – Malignant neoplasm thymus

24. D41.3 – Neoplasm of uncertain behavior urethra

a. 236.99 – Neoplasm of uncertain behavior other and unspecified urinary organs

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 13 of 35

c. 189.3 – Malignant neoplasm urethra

25. D43.3 – Neoplasm of uncertain behavior cranial nerves

a. 237.9 – Neoplasm of uncertain behavior other and unspecified nervous system

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 192.9 – Malignant neoplasm nervous system NOS

26. D44.0 – Neoplasm of uncertain behavior thyroid gland

a. 237.4 – Neoplasm of uncertain behavior other and unspecified endocrine glands

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 193 – Malignant neoplasm thyroid

27. D44.2 – Neoplasm of uncertain behavior parathyroid gland

a. 237.4 – Neoplasm of uncertain behavior other and unspecified endocrine glands

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 194.1 – Malignant neoplasm parathyroid

28. D44.6 – Neoplasm of uncertain behavior carotid body

a. 237.3 – Neoplasm of uncertain behavior paraganglia

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 171.9 – Malignant neoplasm soft tissue NOS

29. D44.7 – Neoplasm of uncertain behavior aortic body and other paraganglia

a. 237.3 – Neoplasm of uncertain behavior paraganglia

b. For the purposes of organ and IREP model selection in EEOICPA, cell behavior is not 

relevant. Only the location of the cancer is important for determining the organ and IREP 

model selection. Therefore, the location-specific malignant neoplasm is used.

c. 171.9 – Malignant neoplasm soft tissue NOS
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 14 of 35

30. D45 – Polycythemia vera

a. Corresponds to multiple ICD-9 codes

i. 207.1 – Chronic erythremia

ii. 238.4 – Polycythemia

b. Erythremia is a chronic form of polycythemia. For use in EEOICPA, the only difference is 

the IREP model used for the two ICD-9 codes (i.e., 207.1 – leukemia, excluding chronic 

lymphocytic leukemia, and 238.4 – bone). NIOSH-Interactive RadioEpidemiological 

Program (NIOSH-IREP) Technical Documentation, Final Report (NIOSH 2002, Table 4)

provides the IREP model for 207.1 but does not list one for 238.4. The IREP model used 

for 238.4 was provided by a DOL-obtained medical opinion indicating it is a type of bone 

cancer (DOL 2002) Therefore, ORAUT-OTIB-0005 uses the IREP model for bone for 

238.4.

c. 238.4 – Polycythemia

31. D47.01 – Cutaneous mastocytosis

a. 238.5 – Mastocytosis NOS

b. Mast cell neoplasms are assumed to be associated with location (see C96.2) and 

cutaneous mastocytosis appears to be associated with the skin. The cancer model is 

specified as the lymphoma model for 238.5 in NIOSH (2002) Table 4, which is the same 

model used for C96.2. Because there is no skin region in ICD-9 code 202.6, the ICD-9 

code used for C96.2, ICD-9 code 202.1 – mycosis fungoides will be used. This might not 

be a good fit from a medical perspective, but the correct organs and cancer models can be 

selected from this code.

c. 202.1 – Mycosis fungoides

32. D47.02 – Systemic mastocytosis

a. 238.5 – Mastocytosis NOS

b. This type of mastocytosis involves the entire body and not one specific location. This 

corresponds to a mastocytosis not elsewhere specified.

c. 238.5 – Mastocytosis NOS

33. D47.4 – Osteomyelofibrosis

a. 289.89 – Unspecified diseases of blood and blood-forming organs

b. The ICD-9 code for myelofibrosis, 289.83, uses the same internal organ, external organ, 

and IREP model as 289.89.

c. 289.89 – Unspecified diseases of blood and blood-forming organs

34. D47.Z2 – Castleman disease

a. 238.79 – Neoplasm of uncertain behavior of other lymphatic/hematopoietic tissue
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 15 of 35

b. This cancer did not have its own designation under ICD-9. Therefore, it would have fallen 

into an “other” category and 238.79 appears to be the correct ICD-9 “other” category.

c. 238.79 – Neoplasm of uncertain behavior of other lymphatic/hematopoietic tissue

35. D48.2 – Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system

a. 238.1 – Neoplasm of uncertain behavior of soft tissue

b. ICD-9 code 238.1 requires a medical review for the internal organ, uses the remainder for 

the external organ and the connective tissue IREP model, which comes from NIOSH

(2002), Table 4. Because ICD-10 specifically separated these nerve cells out of the soft 

tissue group, a more appropriate ICD-9 code can be found. The ICD-9 code 237.7 –

neurofibromatosis is grouped under the neoplasm of uncertain behavior code 237, but 

uses the nervous system IREP model instead of the connective tissue model.

c. 237.7 – Neurofibromatosis

36. D49.2 – Neoplasm of unspecified behavior of bone, soft tissue, and skin

a. 239.2 – Unspecified neoplasm of bone, soft tissue, and skin NOS

b. These ICD-10 and ICD-9 codes are an identical cell type match, so the same method will 

be used to provide the different organ selections in ORAUT-OTIB-0005, one option for 

bone and one for skin. Soft tissue neoplasms of unspecified behavior are covered by all 

other D49 cancers.

c. 239.2 – Unspecified neoplasm of bone, soft tissue, and skin NOS

37. D49.511 to D49.519 – Neoplasm of uncertain behavior of kidney

a. 239.5 – Unspecified neoplasm of genitourinary organs (male and female)

b. Because the ICD-10 cancer description specifies the kidney, ICD-9 code 236.91 –

neoplasm of uncertain behavior of kidney, is more appropriate. The internal organ, 

external organ, and IREP model used for ICD-9 code 236.91 are identical to the codes 

used for 189.0 – malignant neoplasm of kidney.

c. 236.91 – Neoplasm of uncertain behavior of kidney

38. D49.59 – Neoplasm of unspecified behavior of other genitourinary organ

a. 239.5 – Unspecified neoplasm of genitourinary organs (male and female)

b. In accordance with Table 4 in NIOSH (2002), ORAUT-OTIB-0005 separates ICD-9 code 

239.5 into male and female for organ selection. Therefore, the same should be done for 

D49.59.

c. 239.5 – Unspecified neoplasm of genitourinary organs (male and female)

39. D49.7 – Neoplasm of unspecified behavior of endocrine glands and other parts of nervous 

system

a. 239.7 – Unspecified neoplasm of brain, nervous system, and endocrine glands NOS
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 16 of 35

b. For ICD-9 code 239.7, multiple organ selections are provided in ORAUT-OTIB-0005 due to 

the number of specific organs listed in the cancer description. However, ICD-10 code 

D49.7 does not include the brain in its description. Instead, ICD-10 uses code D49.6 –

neoplasm of unspecified behavior of brain. Therefore, the brain will not be included for 

ICD-10 code D49.7.

c. 239.7 – Unspecified neoplasm of brain, nervous system, and endocrine glands NOS, 

excluding an option for the brain.

40. D74.0 – Congenital methemoglobinemia

a. 289.7 – Essential thrombocytosis

b. ICD-10 code D74 contains three subcodes for methemoglobinemia: D74.0 – congenital 

methemoglobinemia, D74.8 – other methemoglobinemias, and D74.9 –

methemoglobinemia, unspecified. Although it is not clear if this disease should be 

classified as a cancer, it corresponds to a disease that EEOICPA recognizes as a cancer, 

so it will be retained. However, by separating the congenital form from the other forms of 

the disease, it is clear that D74.0 is not associated with radiation injury, is thus not 

applicable to EEOICPA, and should be removed.

c. Remove D74.0

41. D77 – Other disorders of blood and blood-forming organs in diseases classified elsewhere

a. 289.89 – Unspecified diseases of blood and blood-forming organs

b. This ICD-10 code includes a note indicating that the underlying disease should be coded 

first and then code D77 is used as a manifestation code. This means that D77 describes 

the manifestation of an underlying disease, not the disease itself. Therefore, it should be 

removed because it is not applicable to EEOICPA.

c. Remove D77

3.2 PRIMARY LYMPHOMA ICD-10 CODES

In 2006, after consulting with an associate professor of medicine, board certified in hematology and a 

member of the International Commission on Radiological Protection Committee 2 responsible for 

internal dosimetry models, NIOSH developed technical information bulletin OCAS-TIB-0012, Selection 

for Internal and External Dosimetry Target Organs for Lymphatic/Hematopoietic Cancers (NIOSH 

2006), to specify the appropriate organs to use for lymphatic and hematopoietic cancers. For 

lymphatic cancers (ICD-9 codes 200 to 202), NIOSH (2006) used three schemes to designate the 

applicable internal and external organs:

• Systemic. The scheme uses the same internal and external organs for every region of the 

body. An example of these is code 200.0 (nodular lymphoma).

• Location specific. The applicable internal and external organ for these is based on the region 

of the body in which the cancer is located. The regions and the organs are the same for each 

instance of this type with the fifth digit of the ICD-9 code indicating the applicable region. An 

example of these is any of the 201 codes (Hodgkin lymphoma).
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 17 of 35

• Unique. An example of this is code 202.1 (mycosis fungoides). The unique nature of this 

cancer is that it is a lymphoma that arises in the skin. Therefore, the internal and external 

target organs were chosen to be the skin.

Reexamining these schemes is beyond the scope of this report. Therefore, this report assumes that

the organs and models used in ORAUT-OTIB-0005 are accurate and simply attempts to determine 

the most appropriate ICD-9 code to correspond to each ICD-10 code. Due to the number of questions 

associated with lymphoma from the initial review, it was decided to document the rationale for each of 

the lymphoma cancers rather than just those with questions. Where appropriate and to avoid 

repetition, the ICD-10 codes for lymphomas are grouped together in this report and discussed as a 

group.

1. C81 – Hodgkin lymphoma

a. 201 – Hodgkin’s disease

b. All ICD-10 C81 subcodes represent forms of Hodgkin lymphoma and correspond to ICD-9 

201 subcodes, which also represent Hodgkin lymphomas. Under OCAS-TIB-0012, 

Selection for Internal and External Dosimetry Target Organs for Lymphatic/Hematopoietic 

Cancers (NIOSH 2006), all Hodgkin lymphomas use the location-specific scheme. All of 

the C81 subcodes include essentially the same location information as the 201 subcodes, 

so the C81 subcodes will correspond to the 201 subcodes listed in the supporting 

spreadsheet [ORAUT (2019)]

c. 201 – Hodgkin’s disease

2. C82 – Follicular lymphoma

a. 202.0 – Nodular lymphoma

b. According to WHO (2016), C82 is a category for “Follicular (nodular) non-Hodgkin 

lymphoma.” All the C82 cancers crosswalk to ICD-9 codes 202.0 – nodular lymphoma and 

202.8 – lymphoma not elsewhere specified. All the C82 ICD-10 codes have the word 

“follicular” in the name, and the WHO category title correlates that with “nodular” 

lymphoma. In addition, ICD-9 codes 202.0 and 202.8 use the same internal organ, 

external organ, and IREP model.

c. 202.0 – Nodular lymphoma

3. C83.0 – Small cell B-cell lymphoma

a. 200.8 – Mixed lymphosarcoma

b. ICD-9 code 200.8 uses the location-specific scheme, and small cell lymphoma are found 

mostly in the lymph nodes and spleen. As such, it appears to be location specific just like 

lymphosarcoma.

c. 200.8 – Mixed lymphosarcoma

4. C83.1 – Mantle cell lymphoma

a. 200.4 – Mantle cell lymphoma
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 18 of 35

b. The ICD-10 and ICD-9 codes directly correspond and no issue was raised during the initial 

review.

c. 200.4 – Mantle cell lymphoma

5. C83.30 – Diffuse large B-cell lymphoma, unspecified site

a. 200.00 – Reticulosarcoma unspecified extranodal organ

b. See discussion for C83.31 to C83.39. 

c. C83.30 corresponds to 200.00 – Reticulosarcoma unspecified extranodal organ

6. C83.31 to C83.39 – Diffuse large B-cell lymphoma, known site

a. Corresponds to multiple ICD-9 codes

i. 200.0 – Reticulosarcoma

ii. 200.5 – Primary central nervous system lymphoma

iii. 200.7 – Large cell lymphoma

b. ICD-9 codes 200.0 and 200.7 use the location-specific scheme, while 200.5 uses the 

systemic scheme. The majority of C83.3 subcodes correspond to only 200.0 and/or 200.7, 

which use the same internal organ, external organ, and IREP model. However, ICD-10 

subcode C83.39 (extranodal and solid organ sites) corresponds to 200.5 as well. ICD-9 

code 200.5 specifies a location of the central nervous system. Because the possible 

locations for C83.39 are disseminated throughout the body, ICD-9 code 200.00 or 200.70 

for unspecified locations correspond to C83.39. In addition, ICD-10 code C83.30 only 

corresponds to 200.00, which as stated before uses the same organs and IREP model as 

200.7. Therefore, the 200.7 group of codes for “large cell” lymphomas will be used for all 

ICD-10 codes except C83.30, which corresponds to ICD-9 code 200.00.

c. C83.31 to C83.39 correspond to 200.7 – Large cell lymphoma

7. C83.5 – Lymphoblastic (diffuse) lymphoma

a. 200.1 – Lymphosarcoma

b. Lymphosarcoma was specially mentioned in NIOSH (2005) as being location specific. 

Because C83.5 corresponds to 200.1, it implies a location-specific scheme is appropriate.

c. 200.1 – Lymphosarcoma

8. C83.7 – Burkitt lymphoma

a. 200.2 – Burkitt’s tumor/lymphoma

b. The ICD-10 and ICD-9 codes directly correspond, and no issue was raised during the initial 

review.

c. 200.2 – Burkitt’s tumor/lymphoma
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 19 of 35

9. C83.8 – Other non-follicular lymphoma

a. Corresponds to multiple ICD-9 codes

i. 200.3 – Marginal zone lymphoma

ii. 200.5 – Primary central nervous system lymphoma

iii. 200.8 – Mixed lymphosarcoma

b. ICD-9 codes 200.3 and 200.5 use the systemic scheme, while 200.8 uses the locationspecific scheme. The general 200 ICD-9 code category is for lymphosarcoma and 

reticulosarcoma, which are named specifically by ICD-9 codes 200.0 and 200.1, 

respectively. Both 200.0 and 200.1 use the location-specific scheme. Because 200.8 is 

for mixed lymphosarcoma (i.e., other named variants of lymphoma), the location scheme is 

appropriate.

c. 200.8 – Mixed lymphosarcoma

10. C83.9 – Non-follicular (diffuse) lymphoma

a. 200.8 – Mixed lymphosarcoma

b. ICD-10 code C83.9 is closely related to C83.8, representing other unspecified types and 

other unnamed types, respectively. Therefore, they will correspond to the same ICD-9 

code.

c. 200.8 – Mixed lymphosarcoma

11. C84.0 – Mycosis fungoides

a. 202.1 – Mycosis fungoides

b. These ICD-10 and ICD-9 codes are direct cell type matches.

c. 202.1 – Mycosis fungoides

12. C84.1 – Sezary disease

a. 202.2 – Sezary’s disease

b. These ICD-10 and ICD-9 codes are direct cell type matches. 

c. 202.2 – Sezary’s disease

13. C84.4 – Peripheral T-cell lymphoma

a. 202.7 – Peripheral T-Cell (cutaneous) lymphoma

b. These ICD-10 and ICD-9 codes are direct cell type matches.

c. 202.7 – Peripheral T-Cell (cutaneous) lymphoma

14. C84.6 to C84.7 – Anaplastic large cell lymphoma (ALK [anaplastic lymphoma kinase] positive 

and negative)

a. 200.6 – Anaplastic large cell lymphomas

b. These ICD-10 and ICD-9 codes are direct cell type matches with the only difference being 

ALK positive or negative, which has no effect for the purposes of EEOICPA.

c. 200.6 – Anaplastic large cell lymphomas
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 20 of 35

15. C84.9 – Mature NK/T [natural killer T-cell] lymphomas, unspecified

a. 202.8 – Other lymphomas not elsewhere classified

b. ICD-9 use of “not elsewhere classified” corresponds to ICD-10 use of “unspecified.”

c. 202.8 – Other lymphomas not elsewhere classified

16. C84.A – Cutaneous T-cell lymphoma, unspecified

a. 202.8 – Other lymphomas not elsewhere classified

b. This is a lymphoma arising in the skin. From a medical perspective, a crosswalk to the 

generic 202.8 might make sense, but for the purposes of EEOICPA it would appear the 

appropriate surrogate organ would be the skin. Therefore, for EEOICPA, this code will 

correspond to 202.1 – mycosis fungoides to provide the appropriate target organs rather 

than important medical information.

c. 202.1 – Mycosis fungoides

17. C84.Z – Other mature T/NK-cell lymphomas

a. 202.8 – Other lymphomas not elsewhere classified

b. This code is very similar to ICD-10 code C84.9. The only difference is that the actual cell 

type is known but not listed instead of unspecified. Therefore, both ICD-10 codes 

correspond to the same ICD-9 codes.

c. 202.8 – Other lymphomas not elsewhere classified

18. C85.1 – Unspecified B-cell lymphoma

a. 202.8 – Other lymphomas not elsewhere classified

b. ICD-9 use of “not elsewhere classified” corresponds to ICD-10 “unspecified.”

c. 202.8 – Other lymphomas not elsewhere classified

19. C85.2 – Mediastinal (thymic) large B-cell lymphoma

a. Correspond to multiple ICD-9 codes

i. 200.7 – Large cell lymphomas

ii. 202.8 – Other lymphomas not elsewhere classified

b. As stated before, 202.8 is a generic classification for unspecified or other lymphomas. 

However, 200.7 appears to correspond better, as it specifies large cell lymphoma. 

Additionally, ICD-10 code C83.3 – large B-cell lymphoma is similar to this code (though 

this one is more specific) and corresponds to 200.7.

c. 200.7 – Large cell lymphomas

20. C85.8 – Other specified types of non-Hodgkin lymphoma

a. 202.8 – Other lymphomas not elsewhere classified

b. ICD-9 use of “not elsewhere classified” corresponds to ICD-10 “other specified.”

c. 202.8 – Other lymphomas not elsewhere classified
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 21 of 35

21. C85.9 – Non-Hodgkin lymphoma, unspecified

a. 202.8 – Other lymphomas not elsewhere classified

b. ICD-9 use of “not elsewhere classified” corresponds to ICD-10 “unspecified.”

c. 202.8 – Other lymphomas not elsewhere classified

22. C86.0 – Extranodal NK/T-cell lymphoma, nasal type

a. 202.81 – Other lymphomas not elsewhere classified, head

b. All of the 202.8 ICD-9 subcodes identify specific areas of the body; however; all 202.8 

subcodes use the same internal organ, external organ, and IREP model. Therefore, the 

specific location identified in C86.0 does not affect the internal organ, external organ, and 

IREP selection.

c. 202.81 – Other lymphomas not elsewhere classified, head

23. C86.1 – Hepatosplenic T-cell lymphoma

a. 202.87 – Other lymphomas not elsewhere classified, spleen

b. All of the 202.8 ICD-9 subcodes identify specific areas of the body; however; all 202.8 

subcodes use the same internal organ, external organ, and IREP model. Therefore, the 

specific location identified in C86.1 does not affect the internal organ, external organ, and 

IREP selection.

c. 202.87 – Other lymphomas not elsewhere classified, spleen

24. C86.2 – Enteropathy-type (intestinal) T-cell lymphoma

a. 202.83 – Other lymphomas not elsewhere classified, abdominal

b. All of the 202.8 ICD-9 subcodes identify specific areas of the body; however; all 202.8 

subcodes use the same internal organ, external organ, and IREP model. Therefore, the 

specific location identified in C86.2 does not affect the internal organ, external organ, and 

IREP selection.

c. 202.83 – Other lymphomas not elsewhere classified, abdominal

25. C86.3 – Subcutaneous panniculitis-like T-cell lymphoma

a. 202.83 – Other lymphomas not elsewhere classified, abdominal

b. All of the 202.8 ICD-9 subcodes identify specific areas of the body; however; all 202.8 

subcodes use the same internal organ, external organ, and IREP model. Therefore, the 

specific location identified in C86.3 does not affect the internal organ, external organ, and 

IREP selection.

c. 202.80 – Other lymphomas not elsewhere classified, unspecified extranodal organ

26. C86.4 – Blastic NK-cell lymphoma

a. 202.80 – Other lymphomas not elsewhere classified, unspecified extranodal organ
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 22 of 35

b. All of the 202.8 ICD-9 subcodes identify specific areas of the body; however; all 202.8 

subcodes use the same internal organ, external organ, and IREP model. Therefore, the 

specific location identified in C86.4 does not affect the internal organ, external organ, and 

IREP selection.

c. 202.80 – Other lymphomas not elsewhere classified, unspecified extranodal organ

27. C86.5 – Angioimmunoblastic T-cell lymphoma

a. 200.80 – Other variants of mixed lymphosarcoma of unspecified extranodal and solid 

organs

b. Although the corresponding ICD-9 code follows the location specific scheme, it is also a 

general code for unspecified sites. In addition, the internal organ, external organ, and 

IREP model are the most claimant-favorable location. The only difference between the 

claimant-favorable location scheme and the systemic scheme is the external organ, thyroid 

and thymus, respectively. This difference does not warrant changing the corresponding 

ICD-9 code.

c. 200.80 – Other variants of mixed lymphosarcoma of unspecified extranodal and solid 

organs

28. C86.6 – Primary cutaneous CD30-positive T-cell proliferations

a. 200.80 – Other variants of mixed lymphosarcoma of unspecified extranodal and solid 

organs

b. This cancer appears to originate in the skin; as such, the appropriate surrogate organ 

would be the skin. Therefore, for EEOICPA, this code will correspond to 202.1 – mycosis 

fungoides to provide the appropriate target organs rather than important medical 

information.

c. 202.1 – Mycosis fungoides

29. C88.0 – Waldenstrom macroglobulinemia

a. 273.3 – Waldenstrom macroglobulinemia

b. These ICD-10 and ICD-9 codes are direct cell type matches.

c. 273.3 – Waldenstrom macroglobulinemia

30. C88.2 – Heavy chain disease

a. Corresponds to multiple ICD-9 codes

i. 203.80 – Other immunoproliferative neoplasms, without remission

ii. 203.81 – Other immunoproliferative neoplasms, with remission

b. The only difference between ICD-9 codes 203.80 and 203.81 is with or without remission. 

This does not affect the organ and IREP model selection for EEOICPA.

c. 203.80 – Other immunoproliferative neoplasms without remission
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 23 of 35

 

31. C88.3 – Immunoproliferative small intestinal disease

a. 203.80 – Other immunoproliferative neoplasms without remission

b. This is the only ICD-9 code for immunoproliferative disease. 

c. 203.80 – Other immunoproliferative neoplasms without remission

32. C88.4 – Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

(MALT-lymphoma)

a. 200.30 – Marginal zone lymphoma, unspecified

b. This is the only ICD-9 code for marginal zone lymphoma. 

c. 200.30 – Marginal zone lymphoma, unspecified

33. C88.8 – Other malignant immunoproliferative diseases

a. Corresponds to multiple ICD-9 codes

i. 203.80 – Other immunoproliferative neoplasms without remission

ii. 238.79 – Other lymphatic and hematopoietic tissue disease

b. The only difference between these two ICD-9 codes is the IREP model selection. ICD-9 

code 238.79 includes the bone model while 203.80 does not. The bone model was 

included for 238.79 because myelodysplastic syndrome was considered an “other 

lymphatic and hematopoietic tissue disease”. Since myelodysplastic syndrome has a 

specific ICD-10 code, 203.80 IREP model selection corresponds better to C88.8.

c. 203.80 – Other immunoproliferative neoplasms without remission

34. C88.9 – Malignant immunoproliferative disease, unspecified

a. 203.80 – Other immunoproliferative neoplasms without remission

b. See discussion for C88.8. 

c. 203.80 – Other immunoproliferative neoplasms without remission

A complete list of all corresponding ICD-9 and ICD-10 codes can be found in ORAUT (2019). 

4.0 SECONDARY CANCER ICD-10 CODES

The ICD-9 coding system currently used in ORAUT-OTIB-0005 has a general range of codes from 

196 to 198 to describe only secondary cancers, with two exceptions, 511.81 and 789.51. These two 

ICD-9 codes are outside the general range for secondary cancers and were determined to correspond 

with ICD-9 codes 197.2 and 197.6, respectively, and therefore have the same likely primaries. 

Similarly, the ICD-10 coding system has a general range of codes from C77 to C79, including C7B, to 

describe secondary cancers, again with two exceptions, J91.0 and R18.0. When evaluating 

secondary cancers for EEOICPA all likely primary cancers must be assessed, so the list of likely 

primary cancers in NIOSH (2002) must be converted to ICD-10 codes.

NIOSH (2002) Table 7 lists the likely primary cancers and their ICD-9 codes for EEOICPA

(reproduced as Table 4-1 below). This list was generated by determining which primary cancers 

produced approximately 75% of each secondary cancer in the U.S. population (males and females 

were considered separately). In NIOSH (2002) Table 7, the ICD-9 secondary cancer codes are 

divided into four digit codes (i.e., one decimal place), while the primary codes are listed as three-digit 

codes (i.e., no decimal point). The likely primary cancer listings created for the corresponding ICD-10 
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 24 of 35

codes attempts to retain this level of detail, rather than subdivide further, in order to remain accurate 

in relation to the original statistics. 

Table 4-1. NIOSH (2002) Table 7. 

Secondary cancer location (ICD-9 code) ICD-9 code of likely primary cancers

Lymph nodes of head, face, and neck (196.0) 141,142(M), 146(M), 149(F), 161(M), 162, 172, 173, 174(F), 

193(F)

Intrathoracic lymph nodes (196.1) 150(M), 162, 174(F)

Intra-abdominal lymph nodes (196.2) 150(M), 151(M), 153, 157(F), 162, 174(F), 180(F), 185(M), 

189, 202(F)

Lymph nodes of axilla and upper limb (196.3) 162, 172, 174(F)

Inguinal and lower limb lymph nodes (196.5) 154(M), 162, 172, 173(F), 187(M)

Intrapelvic lymph nodes (196.6) 153(M), 154(F), 162(M), 180(F), 182(F), 185(M), 188

Lymph nodes of multiple sites (196.8) 150(M), 151(M), 153(M), 162, 174(F)

Lymph nodes, site unspecified (196.9) 150(M), 151, 153, 162, 172, 174(F), 185(M)

Lung (197.0) 153, 162, 172(M), 17 (F), 185(M), 188(M), 189

Mediastinum (197.1) 150(M), 162, 174(F)

Pleura (197.2) 150(M), 153(M), 162, 174(F), 183(F), 185(M), 189(M)

Other respiratory organs (197.3) 150, 153(M), 161, 162, 173(M), 174(F), 185(M), 193(F)

Small intestine, including duodenum (197.4) 152, 153, 157, 162, 171, 172(M), 174(F), 183(F), 189(M)

Large intestine and rectum (197.5) 153, 154, 162, 174(F), 183(F), 185(M)

Retroperitoneum and peritoneum (197.6) 151, 153, 154(M), 157, 162(M), 171, 174(F), 182(F), 183(F)

Liver, specified as secondary (197.7) 151 (M), 153, 154(M), 157, 162, 174(F)

Other digestive organs (197.8) 150 (M), 151, 153, 157, 162, 174 (F), 185 (M)

Kidney (198.0) 153, 162, 174 (F), 180 (F), 185 (M), 188, 189, 202 (F)

Other urinary organs (198.1) 153, 174 (F), 180 (F), 183 (F), 185 (M), 188, 189 (F)

Skin (198.2) 153, 162, 171 (M), 172, 173 (M), 174 (F), 189 (M)

Brain and spinal cord (198.3) 162, 172 (M), 174 (F)

Other parts of nervous system (198.4) 162, 172 (M), 17 4 (F), 185 (M), 202

Bone and bone marrow (198.5) 162, 174 (F), I 85 (M)

Ovary (198.6) 153 (F), 174 (F), 183 (F)

Suprarenal gland (198.7) 153 (F), 162, 174 (F)

Other specified sites (198.8) 153, 162, 172 (M), 174 (F), 183 (F), 185 (M), 188 (M)

In addition, it is not clear if the secondary cancers evaluated in NIOSH (2002) were based on 

ICD-9 codes or simply based on the location of the secondary cancer for each grouping. With the 

75% criteria mentioned above, it is clear that the listings are based on the predominant cancers in 

the group rather than the more unusual types of cancer belonging to a group. Therefore, the 

NIOSH (2002) Table 7 was converted based the predominant form(s) of cancer in a particular 

group. 

4.1 CORRESPONDING ICD-9 AND ICD-10 SECONDARY CANCER CODES 

To convert NIOSH (2002) Table 7 from ICD-9 codes to ICD-10 codes, all ICD-10 codes describing 

secondary cancers and their corresponding ICD-9 codes were determined first. In ORAUT 

(2019), when an ICD-10 code has a clear one-to-one correspondence to an ICD-9 code, no 

explanation is provided. However, for the ICD-10 codes where the corresponding ICD-9 code is 

not obvious, the rationale is provided below: 

1. C78.7 – Secondary malignant neoplasm of liver and intrahepatic bile duct

a. Corresponds to multiple ICD-9 codes

i. 197.7 – Secondary malignant neoplasm of liver

ii. 197.8 – Secondary malignant neoplasm of other digestive organs
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 25 of 35

b. Primary ICD-9 code 155 is for the liver and intrahepatic ducts while the extrahepatic ducts 

are covered under ICD-9 code 156. Following this logic, 197.7 is the appropriate ICD-9 

code for the liver and intrahepatic bile duct.

c. 197.7 – Secondary malignant neoplasm of liver

2. C79.31 – Secondary malignant neoplasm of the brain

a. 198.3 – Secondary malignant neoplasm of the brain and spinal cord

b. In the ICD-9 coding system the spinal cord was grouped with the brain (i.e., ICD-9 code 

198.3) and cerebral meninges was grouped with other parts of the nervous system (i.e., 

ICD-9 code 198.4). However, in the ICD-10 coding system, secondary malignant 

neoplasm of cerebral meninges was given its own ICD-10 code (see C79.32) and the 

spinal cord was grouped with other parts of the nervous system. To determine which 

ICD-9 code best corresponds with ICD-10 codes C79.31 and C79.32, the claim statistics in 

the NIOSH-Division of Compensation Analysis and Support Claims Tracking System were 

reviewed. These statistics showed that 101 secondary brain cancers, 3 secondary spinal 

cord cancers, 3 secondary cancers of the brain and spinal cord, and 2 secondary cerebral 

meninges cancers have been evaluated under EEOICPA. It is clear that secondary brain 

cancers likely drove the statistics used to create Table 7 in NIOSH (2002). Therefore,

ICD-9 code 198.3 will be used for both C79.31 and C79.32, to stay true to the original 

statistics used to determine the likely primary cancers.

c. 198.3 – Secondary neoplasm of the brain and spinal cord

3. C79.32 – Secondary malignant neoplasm of cerebral meninges

a. 198.4 – Secondary malignant neoplasm of other parts of the nervous system

b. See C79.31.

c. 198.3 – Secondary malignant neoplasm of the brain and spinal cord

The following ICD-10 codes are all subcodes of the C7B group, which corresponds to ICD-9 code

group 209.7. However, the ICD-9 code group 209.7 was added to the ICD-9 coding system in 2009 

and corresponded to ICD-9 codes between 196.0 and 199.1. Therefore, for ICD-9 codes 209.7 the 

corresponding ICD-9 code between 196.0 and 199.1 was used for organ and IREP model selection in 

ORAUT-OTIB-0005. To maintain consistency, C7B ICD-10 subcodes used the coding system from 

DHHS (2009) to determine the corresponding ICD-9 code, as described below.

4. C7B.00 – Secondary carcinoid tumor of unspecified sites

a. 209.70 – Secondary neuroendocrine tumor, unspecified site

b. Use ICD-9 code from DHHS (2009)

c. 199.1 – Malignant neoplasm NOS

5. C7B.01 – Secondary carcinoid tumor of distant lymph nodes

a. 196.0 to 196.9 – Malignant neoplasm of lymph nodes (various locations)

b. Because ICD-10 code C7B.01 does not describe a distinct location, the ICD-9 code for 

unspecified locations will be used.

c. 196.9 – Malignant neoplasm of lymph nodes NOS
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 26 of 35

6. C7B.02 – Secondary carcinoid tumor of liver

a. 209.72 – Secondary neuroendocrine tumor of liver

b. Use ICD-9 code from DHHS (2009).

c. 197.7 – Secondary malignant neoplasm of liver

7. C7B.03 – Secondary carcinoid tumors of bone

a. 209.73 – Secondary neuroendocrine tumor of bone

b. Use ICD-9 code from DHHS (2009).

c. 198.5 – Secondary malignant neoplasm bone

8. C7B.04 – Secondary carcinoid tumors of peritoneum

a. 209.74 – Secondary neuroendocrine tumor of peritoneum

b. Use ICD-9 code from DHHS (2009).

c. 197.6 – Secondary malignant neoplasm peritoneum

9. C7B.09 – Secondary carcinoid tumors of other sites

a. 209.79 – Secondary neuroendocrine tumor of other sites

b. Use ICD-9 code from DHHS (2009).

c. 199.0 – Malignant neoplasm disseminated

10. C7B.1 – Secondary Merkel cell carcinoma 

a. 209.75 – Secondary Merkel cell carcinoma

b. ICD-9 code 209.75 corresponds to ICD-9 code 199, which is the code used when nothing 

is known about the cancer. However, Merkel cell carcinoma is associated with cancer of 

the skin. Therefore, it corresponds better with the ICD-9 code for secondary skin cancer

because the location is known.

c. 198.2 – Secondary malignant neoplasm skin

11. C7B.8 – Other secondary neuroendocrine tumors

a. 209.79 – Secondary neuroendocrine tumor of other sites

b. Use ICD-9 code from DHHS (2009).

c. 199.0 – Malignant neoplasm disseminated

Some of the ICD-10 codes above correspond to ICD-9 code 199, which can be either a primary or 

secondary. As such, there are no likely primary cancers listed in Table 7 of NIOSH (2002) for these 

cancers (i.e., C7B.00, C7B.09, and C7B.8), so none will be listed in the ICD-10 version.

4.2 CORRESPONDING ICD-9 AND ICD-10 LIKELY PRIMARY CANCER CODES

Many of the likely primary cancers in NIOSH (2002) Table 7 are a likely primary cancer for more than 

one secondary cancer. Table 4-2 lists all of the likely primary cancers with their ICD-9 code, cancer 

descriptions, and corresponding ICD-10 codes as determined in Section 2.0.
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 27 of 35

 

4.3 ICD-10 VERSION OF NIOSH (2002) TABLE 7 

Using the information in NIOSH (2002) Table 7 and ORAUT (2019), Table 7 can be converted to 

ICD-10 codes for secondary cancers and likely primary cancers, as shown in Table 4-3.

Table 4-3 is considered the official list of likely primary cancers, and is listed as such in 42 CFR 

Part 81. However, in some cases, more than one likely primary cancer code points to identical 

internal organs, external organs, and IREP models. Therefore, for ease of use in EEOICPA, some of 

Table 4-2. Corresponding ICD-9 and ICD-10 likely primary cancer codes.

ICD-9 

code Cancer description Corresponding ICD-10 code(s)

141 Tongue C01, C02

142 Major salivary glands C07, C08

146 Oropharynx C09, C10

149 Other and ill-defined sites within the lip, oral 

cavity, and pharynx

C14

150 Esophagus C15

151 Stomach C16

152 Small intestine C17

153 Colon C18

154 Rectum C19, C20, C21

157 Pancreas C25

161 Larynx C32

162 Trachea, bronchus and lung C33, C34

171 Connective and other soft tissue C49

172 Malignant melanoma C43, D03

173 Non-melanoma skin C44

174 Breast C50

180 Cervix uteri C53

182 Uterus C54

183 Ovary and other uterine adnexa C56, C57

185 Prostate C61

187 Male genital organs C60, C63

188 Bladder C67

189 Kidney C64, C65, C66, C68

193 Thyroid C73

202 Other malignant neoplasms of lymphoid and 

histiocytic tissue

C82, C84 (excluding C84.6, C84.7), C85 (excluding 

C85.2), C86 (excluding C86.5), C91.4 C96

Table 4-3. ICD-10 version of IREP Technical Documentation Table 7. 

ICD-10 

code Secondary cancer description ICD-10 codes of likely primary cancers

C77.0 Lymph nodes of head, face and neck C01, C02, C07(M), C08(M), C09(M), C10(M), C14(F), 

C32(M), C33, C34, C43, C44, C50(F), C73(F), D03

C77.1 Intrathoracic lymph nodes C15(M), C33, C34, C50(F)

C77.2 Intra-abdominal lymph nodes C15(M), C16(M), C18, C25(F), C33, C34, C50(F), C53(F), 

C61(M), C64, C65, C66, C68, C82(F), C84(F)(excluding 

C84.6, C84.7), C85(F) (excluding C85.2), C86(F) (excluding 

C86.5), C91.4(F), C96(F)

C77.3 Axilla and upper limb lymph nodes C33, C34, C43, C50(F), D03

C77.4 Inguinal and lower limb lymph nodes C19(M), C20(M), C21(M), C33, C34, C43, C44(F), C60(M), 

C63(M), D03

C77.5 Intrapelvic lymph nodes C18(M), C19(F), C20(F), C21(F), C33(M), C34(M), C53(F), 

C54(F), C61(M), C67
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 28 of 35

 

ICD-10 

code Secondary cancer description ICD-10 codes of likely primary cancers

C77.8 Lymph nodes of multiple regions C15(M), C16(M), C18(M), C33, C34, C50(F)

C77.9 Lymph nodes, unspecified C15(M), C16, C18, C33, C34, C43, C50(F), C61(M), D03

C78.0 Lung C18, C33, C34, C43(M), C50(F), C61(M), C67(M), C64, C65, 

C66, C68, D03(M)

C78.1 Mediastinum C15(M), C33, C34, C50(F)

C78.2 Pleura C15(M), C18(M), C33, C34, C50(F), C56(F), C57(F), 

C61(M), C64(M), C65(M), C66(M), C68(M)

C78.3 Other and unspecified respiratory 

organs

C15, C18(M), C32, C33, C34, C44(M), C50(F), C61(M), 

C73(F)

C78.4 Small intestine C17, C18, C25, C33, C34, C49, C43(M), C50(F), C56(F), 

C57(F), C64(M), C65(M), C66(M), C68(M), D03(M)

C78.5 Large intestine and rectum C18, C19, C20, C21, C33, C34, C50(F), C56(F), C57(F), 

C61(M)

C78.6 Retroperitoneum and peritoneum C16, C18, C19(M), C20(M), C21(M), C25, C33(M), C34(M), 

C49, C50(F), C54(F), C56(F), C57(F)

C78.7 Liver and intrahepatic bile duct C16(M), C18, C19(M), C20(M), C21(M), C25, C33, C34, 

C50(F)

C78.8 Other and unspecified digestive 

organs

C15(M), C16, C18, C25, C33, C34, C50(F), C61(M)

C79.0 Kidney C18, C33, C34, C50(F), C53(F), C61(M), C67, C64, C65, 

C66, C68, C82(F), C84(F) (excluding C84.6, C84.7), C85(F) 

(excluding C85.2), C86(F) (excluding C86.5), C91.4(F), 

C96(F)

C79.1 Bladder and urinary organs C18, C50(F), C53(F), C56(F), C57(F), C61(M), C67, C64(F), 

C65(F), C66(F), C68(F)

C79.2 Skin C18, C33, C34, C49(M), C43, C44(M), C50(F), C64(M), 

C65(M), C66(M), C68(M), D03

C79.3 Brain C33, C34, C43(M), C50(F), D03(M)

C79.4 Other and unspecified parts of 

nervous system

C33, C34, C43(M), C50(F), C61(M), C82, C84 (excluding 

C84.6, C84.7), C85 (excluding C85.2), C86 (excluding 

C86.5), C91.4, C96, D03(M)

C79.5 Bone and bone marrow C33, C34, C50(F), C61(M)

C79.6 Ovary C18(F), C50(F), C56(F), C57(F)

C79.7 Adrenal gland C18(F), C33, C34, C50(F)

C79.8 Other sites C18, C33, C34, C43(M), C50(F), C56(F), C57(F), C61(M), 

C67(M), D03(M)

C79.9 Unspecified sites C18, C33, C34, C43(M), C50(F), C56(F), C57(F), C61(M), 

C67(M), D03(M)

C7B.01 Carcinoid tumor of distant lymph 

nodes

C15(M), C16, C18, C33, C34, C43, C50(F),C61(M), D03

C7B.02 Carcinoid tumor of liver C16(M), C18, C19(M), C20(M), C21(M), C25, C33, C34, 

C50(F)

C7B.03 Carcinoid tumor of bone C33, C34, C50(F), C61(M)

C7B.04 Carcinoid tumor of peritoneum C16, C18, C19(M), C20(M), C21(M), C25, C33(M), C34(M), 

C49, C50(F), C54(F), C56(F), C57(F)

C7B.1 Merkel cell carcinoma C18, C33, C34, C49(M), C43, C44(M), C50(F), C64(M), 

C65(M), C66(M), C68(M), D03

J91.0 Malignant pleural effusion C15(M), C18(M), C33, C34, C50(F), C56(F), C57(F), 

C61(M), C64(M), C65(M), C66(M), C68(M)

R18.0 Malignant ascites C16, C18, C19(M), C20(M), C21(M), C25, C33(M), C34(M), 

C49, C50(F), C54(F), C56(F), C57(F)

the codes in the table can be consolidated into a single code. This consolidation does not accurately 

reflect the likely primary cancers but would result in the appropriate assessment being performed. 
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 29 of 35

Table 4-4 shows the organs and cancer models for each of the likely primary ICD-10 codes. The 

bolded ICD-10 codes represent the likely primary cancer code that will be used for EEOICPA dose 

reconstructions.

Table 4-5 shows the likely primary ICD-10 codes that can be combined due to the use of the same 

internal organ, external organ, and IREP model.
 

Document No. ORAUT-RPRT-0098 Revision No. 0

0 Effective Date: 

07/22/2019 Page 30 of 35

Table 4-4. Organ and IREP model selection for likely primary ICD-10 codes. 

ICD-9 

code ICD-10 code Internal organ External organ IREP model

141 C01a Highest non-met org/tissue Thyroid/remainder Oral cavity and pharynx

141 C02 Highest non-met org/tissue Thyroid/remainder Oral cavity and pharynx

141 C02 LNET Thyroid/remainder Oral cavity and pharynx

142 C07a Highest non-met org/tissue Thyroid/remainder Oral cavity and pharynx

142 C08 Highest non-met org/tissue Thyroid/remainder Oral cavity and pharynx

146 C09 LNET Esophagus Oral cavity and pharynx

146 C010 ET2 Esophagus Oral cavity and pharynx

149 C14 ET2 Esophagus Oral cavity and pharynx

149 C14 LNET Esophagus Oral cavity and pharynx

150 C15 Esophagus/stomach Esophagus/stomach Esophagus/stomach

151 C16 Stomach Stomach Stomach

152 C17 SI Stomach All digestive

153 C18 LLI Colon Colon

153 C18 ULI Colon Colon

153 C18 Colon Colon Colon

154 C19a LLI Colon Rectum

154 C20a LLI Colon Rectum

154 C21 LLI Colon Rectum

157 C25 Pancreas Stomach Pancreas

161 C32 ET2 Esophagus Other respiratory

162 C33a Lung Lung Lung

162 C34 Lung Lung Lung

171 C49 Highest non-met org/tissue Thyroid/remainder Connective tissue

172 C43 Skin Skin Malignant melanoma

172 D03a Skin Skin Malignant melanoma

173 C44 Skin Skin Non-melanoma skin-basal cell

173 C44 Skin Skin Non-melanoma skin-squamous cell

174 C50 Breast Breast Breast

180 C53 Uterus Uterus Female genitalia less ovary

182 C54 Uterus Uterus Female genitalia less ovary

183 C56a Ovaries Ovaries Ovary

183 C57 Uterus Ovaries Ovary

183 C57 Ovaries Ovaries Ovary

183 C57 Uterus Uterus Female genitalia less ovary

185 C61 Highest non-met org/tissue Bladder All male genitalia

187 C60 Skin Testes All male genitalia

187 C60 Testes Testes All male genitalia

187 C63a Testes Testes All male genitalia
 

Document No. ORAUT-RPRT-0098 Revision No. 0

0 Effective Date: 

07/22/2019 Page 31 of 35

ICD-9 

code ICD-10 code Internal organ External organ IREP model

188 C67 Bladder Bladder Bladder

189 C64 Kidney Liver Urinary organs less bladder

189 C65a Kidney Liver Urinary organs less bladder

189 C66a Highest non-met org/tissue Liver Urinary organs less bladder

189 C68 Highest non-met org/tissue Liver Urinary organs less bladder

189 C68 Bladder Liver Urinary organs less bladder

193 C73 Thyroid Thyroid Thyroid

202 C82a LN(TH) Thymus/lung Lymphoma and multiple myeloma

202 C84.0-C84.4, C84.A Skin Skin Lymphoma and multiple myeloma

200 C84.6-C84.7a Not Included as likely primary Not applicable Not applicable

202 C84.9, C84.Z LN(TH) Thymus/lung Lymphoma and multiple myeloma

202 C85.1a LN(TH) Thymus/lung Lymphoma and multiple myeloma

200 C85.2a Not Included as likely primary Not applicable Not applicable

202 C85.8-C85.9a LN(TH) Thymus/lung Lymphoma and multiple myeloma

202 C86.0-C86.4a LN(TH) Thymus/lung Lymphoma and multiple myeloma

200 C86.5a Not Included as likely primary Not applicable Not applicable

202 C86.6a Skin Skin Lymphoma and multiple myeloma

204 C91.0-C91.3a Not Included as likely primary Not applicable Not applicable

202 C91.4 Red bone marrow Red bone marrow Lymphoma and multiple myeloma

204 C91.5-C91.Za Not Included as likely primary Not applicable Not applicable

202 C96.0 LN(TH) Skin Lymphoma and multiple myeloma

202 C96.2, C96.A LN(TH) Thyroid Lymphoma and multiple myeloma

202 C96.4, C96.9, C96.Z LN(TH) Thymus/lung Lymphoma and multiple myeloma

a. Code represents ICD-10 primary cancer codes that will not be used for EEOICPA dose reconstructions because they are duplicates of ICD-10 codes that will be used 

for each specified ICD-9 code. 
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 32 of 35

 

Table 4-5. ICD-10 codes with identical organ and IREP model selection. 

ICD-10 code included as 

likely primary

ICD-10 code(s) that can be removed 

from likely primary evaluation

C02 C01 and/or C08

C21 C19 and/or C20

C34 C33

C43 D03

C54 C53

C57 C53 and/or C54 and/or C56

C60 C63

C64 C65

C68 C66

C84 C82 and/or C85 and/or C86

The consolidated ICD-10 version of NIOSH (2002) Table 7 for use in EEOICPA is shown in Table 4-6. 

In the future, if any revisions are made to the organs or models for any ICD-10 codes listed as a likely 

primary cancer, the consolidated table must be reviewed.

5.0 CONCLUSION

Beginning in 2019, DOL will report only ICD-10 codes to describe covered illnesses under EEOICPA 

to NIOSH. Therefore, to maintain consistency in the organ and IREP model selection used in 

EEOICPA, the information in this report and ORAUT (2019) will be used to update ORAUT-OTIB0005 and ORAUT-OTIB-0006 from ICD-9 to ICD-10 codes.
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 33 of 35

 

Table 4-6. ICD-10 version of IREP Technical Documentation Table 7 for use in EEOICPA. 

ICD-10 

code Secondary cancer description ICD-10 codes of likely primary cancers

C77.0 Lymph nodes of head, face and neck C02, C09(M), C10(M), C14(F), C32(M), C34, C43, C44, 

C50(F), C73(F)

C77.1 Intrathoracic lymph nodes C15(M), C34, C50(F)

C77.2 Intra-abdominal lymph nodes C15(M), C16(M), C18, C25(F), C34, C50(F), C53(F), 

C61(M), C64, C68, C84(F)(excluding C84.6, C84.7), 

C91.4(F), C96(F)

C77.3 Axilla and upper limb lymph nodes C34, C43, C50(F)

C77.4 Inguinal and lower limb lymph nodes C21(M), C34, C43, C44(F), C60(M)

C77.5 Intrapelvic lymph nodes C18(M), C21(F), C34(M), C54(F), C61(M), C67

C77.8 Lymph nodes of multiple regions C15(M), C16(M), C18(M), C34, C50(F)

C77.9 Lymph nodes, unspecified C15(M), C16, C18, C34, C43, C50(F), C61(M)

C78.0 Lung C18, C34, C43(M), C50(F), C61(M), C67(M), C64, C68

C78.1 Mediastinum C15(M), C34, C50(F)

C78.2 Pleura C15(M), C18(M), C34, C50(F), C57(F), C61(M), C64(M), 

C68(M)

C78.3 Other and unspecified respiratory 

organs

C15, C18(M), C32, C34, C44(M), C50(F), C61(M), C73(F)

C78.4 Small intestine C17, C18, C25, C34, C49, C43(M), C50(F), C57(F), 

C64(M), C68(M)

C78.5 Large intestine and rectum C18, C21, C34, C50(F), C57(F), C61(M)

C78.6 Retroperitoneum and peritoneum C16, C18, C21(M), C25, C34(M), C49, C50(F), C57(F)

C78.7 Liver and intrahepatic bile duct C16(M), C18, C21(M), C25, C34, C50(F)

C78.8 Other and unspecified digestive organs C15(M), C16, C18, C25, C34, C50(F), C61(M)

C79.0 Kidney C18, C34, C50(F), C53(F), C61(M), C67, C64, C68, 

C84(F)(excluding C84.6, C84.7), C91.4(F), C96(F)

C79.1 Bladder and urinary organs C18, C50(F), C57(F), C61(M), C67, C64(F), C68(F)

C79.2 Skin C18, C34, C49(M), C43, C44(M), C50(F), C64(M), C68(M)

C79.3 Brain C34, C43(M), C50(F)

C79.4 Other and unspecified parts of nervous 

system

C34, C43(M), C50(F), C61(M), C84(excluding C84.6, 

C84.7), C91.4, C96

C79.5 Bone and bone marrow C34, C50(F), C61(M)

C79.6 Ovary C18(F), C50(F), C57(F)

C79.7 Adrenal gland C18(F), C34, C50(F)

C79.8 Other sites C18, C34, C43(M), C50(F), C57(F), C61(M), C67(M)

C79.9 Unspecified sites C18, C34, C43(M), C50(F), C57(F), C61(M), C67(M)

C7B.01 Carcinoid tumor of distant lymph nodes C15(M), C16, C18, C34, C43, C50(F),C61(M)

C7B.02 Carcinoid tumor of liver C16(M), C18, C21(M), C25, C34, C50(F)

C7B.03 Carcinoid tumor of bone C34, C50(F), C61(M)

C7B.04 Carcinoid tumor of peritoneum C16, C18, C21(M), C25, C34(M), C49, C50(F), C57(F)

C7B.1 Merkel cell carcinoma C18, C34, C49(M), C43, C44(M), C50(F), C64(M), C68(M)

J91.0 Malignant pleural effusion C15(M), C18(M), C34, C50(F), C57(F), C61(M), C64(M), 

C68(M)

R18.0 Malignant ascites C16, C18, C21(M), C25, C34(M), C49, C50(F), C57(F)
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 34 of 35

 

REFERENCES 

DHHS (U.S. Department of Health and Human Services), 2009, Conversion Table of New ICD-9-CM 

Codes, Centers for Medicare and Medicaid Services and National Center for Health Statistics, 

Hyattsville, Maryland, October. [SRDB Ref ID: 71531, p. 4]

DOL (U.S. Department of Labor), 2002, Additional Cancers Considered as Primary Cancers, 

EEOICPA Bulletin No. 03-11, Division of Energy Employees, Washington, D.C., November 19. 

[SRDB Ref ID: 145059]

NCHS (National Center for Health Statistics), 2018a, “International Classification of Diseases, Tenth 

Revision, Clinical Modification (ICD-10-CM),” Centers for Disease Control and Prevention, 

Atlanta, Georgia, July 26. [SRDB Ref ID: 176606] 

NCHS (National Center for Health Statistics), 2018b, “2018_I9gem.txt,” General Equivalence Map to 

convert ICD-9 codes to ICD-10 codes, Centers for Disease Control and Prevention, Atlanta, 

Georgia. [SRDB Ref ID: 176111] 

NCHS (National Center for Health Statistics), 2018c, “2018_I10gem.txt,” General Equivalence Map to 

convert ICD-10 codes to ICD-9 codes, Centers for Disease Control and Prevention, Atlanta, 

Georgia. [SRDB Ref ID: 176113] 

NCHS (National Center for Health Statistics), 2018d, Diagnosis Code Set General Equivalence 

Mappings, ICD-10-CM to ICD-9-CM and ICD-9-CM to ICD-10-CM, Documentation and User’s 

Guide, Centers for Disease Control and Prevention, Atlanta, Georgia. [SRDB Ref ID: 176114]

NCHS (National Center for Health Statistics), 2018e, General Equivalence Mappings, Documentation 

for Technical Users, Revised, Centers for Disease Control and Prevention, Atlanta, Georgia. 

[SRDB Ref ID: 176116]

NCHS (National Center for Health Statistics), 2018f, “icd10cm_codes_2018.txt,” 2018 ICD-10-CM 

codes, Centers for Disease Control and Prevention, Atlanta, Georgia. [SRDB Ref ID: 176485] 

NCI (National Cancer Institute), 2019, “Myelodysplastic/Myeloproliferative Neoplasms Treatment 

(PDQ®)–Health Professional Version,” U.S. Department of Health and Human Services, 

Bethesda, Maryland, February 1. [SRDB Ref ID: 176608] 

NIOSH (National Institute for Occupational Safety and Health), 2002, NIOSH-Interactive 

RadioEpidemiological Program (NIOSH-IREP) Technical Documentation, Final Report, Office 

of Compensation Analysis and Support, Cincinnati, Ohio, June 18. [SRDB Ref ID: 22398]

NIOSH (National Institute for Occupational Safety and Health), 2005, “Summary of NIOSH's 

Re-examination of Lymphoma Target Organ Selection,” Cincinnati, Ohio, October 31. [SRDB 

Ref ID: 175842] 

NIOSH (National Institute for Occupational Safety and Health), ca. 2005, Consultant’s Report, Dose 

Reconstruction Project, Office of Compensation Analysis and Support, Cincinnati, Ohio. 

[SRDB Ref ID: 175841]

NIOSH (National Institute for Occupational Safety and Health), 2006, Selection for Internal and 

External Dosimetry Target Organs for Lymphatic/Hematopoietic Cancers, OCAS-TIB-0012,

Rev. 01, Office of Compensation Analysis and Support, Cincinnati, Ohio, February 10. [SRDB 

Ref ID: 29934]
Document No. ORAUT-RPRT-0098 Revision No. 00 Effective Date: 07/22/2019 Page 35 of 35

 

ORAUT (Oak Ridge Associated Universities Team), 2012, Internal Dosimetry Organ, External 

Dosimetry Organ, and IREP Model Selection by ICD-9 Code, ORAUT-OTIB-0005, Rev. 05, 

December 20. [SRDB Ref ID: 121336]

ORAUT (Oak Ridge Associated Universities Team), 2018, Dose Reconstruction from Occupational 

Medical X-Ray Procedures, ORAUT-OTIB-0006, Rev. 05, Oak Ridge, Tennessee, August 13. 

[SRDB Ref ID: 172596]

ORAUT (Oak Ridge Associated Universities Team), 2019, “Support spreadsheet for RPRT-0098,” 

spreadsheet, Oak Ridge, Tennessee, April. [SRDB Ref ID: 175860]

WHO (World Health Organization), 2016, “Malignant neoplasms, stated or presumed to be primary, of 

lymphoid, hoematopoietic and related tissue (C18–C96),” in Chapter 2, “Neoplasms (C00–

D48), Malignant neoplasms (C00–C97),” International Statistical Classification of Diseases 

and Related Health Problems 10th Revision (ICD-10), United Nations, Geneva, Switzerland. 

[SRDB Ref ID: 176607]